Drugs & Targets European Commission authorizes expanded label for Venclyxto to include additional combinations in previously untreated CLL June 05, 2026Vol.52 No.22
Drugs & Targets FDA approves pivekimab sunirine-pvzy for blastic plasmacytoid dendritic cell neoplasm May 29, 2026Vol.52 No.21
Drugs & Targets FDA approves Hepcludex for chronic hepatitis delta virus infection May 29, 2026Vol.52 No.21
Drugs & Targets FDA grants Orphan Drug designation to oxaliplatin delivered via RenovoCath catheter for pancreatic cancer May 29, 2026Vol.52 No.21
Drugs & Targets FDA approves Enhertu in HER2+ early breast cancer for both neoadjuvant and adjuvant treatment May 22, 2026Vol.52 No.20
Drugs & Targets FDA approves Signatera CDx as a companion diagnostic in muscle-invasive bladder cancer May 22, 2026Vol.52 No.20
Drugs & Targets FDA grants priority review to Hyrnuo in first-line HER2-mutated NSCLC May 22, 2026Vol.52 No.20
Drugs & Targets FDA approves oral combination Inqovi plus venetoclax for newly diagnosed AML May 15, 2026Vol.52 No.19
